# Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee

> **NCT01487200** · PHASE2 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 24 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** FX006 10 mg
- **DRUG:** FX006 40 mg
- **DRUG:** FX006 60 mg
- **DRUG:** TCA IR 40

## Key facts

- **NCT ID:** NCT01487200
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487200, "Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01487200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*